CTLA4 and non-small cell lung carcinoma: The CheckMate-73L study has highlighted that in the treatment of unresectable stage III NSCLC patients, the safety of the PD-1/PD-L1+CTLA-4 dual immunotherapy regimen compared to PD-1/PD-L1 inhibitor monotherapy as consolidation therapy after concurrent chemoradiotherapy was evaluated.